Prof. Zhiwei Cao

        Currently my lab focuses on computational modelling of synergistic drugs, antibody drugs and vaccine design. We have obtained funding supports from three National Key R & D projects, two National 973 projects, 2 NSFC projects, one 863 project, two National Infectious Disease projects, and 3 Shanghai municipal projects, with more than 110 SCI papers published and 3 patents granted.

        Prof. Cao acts as the vice chairman of TCM informatics society of Chinese Medicine Association, and the Council member of Shanghai Bioinformatics Society.

Link to ORCID WebSite. []

Educational background

Sep,1991 ~ Jun,1995 Bs.
Dept. of Biochemistry, Nankai University, Tianjin, China

Sep,1995 ~ Jun,1998 Ms.
Dept. of Biochemistry, Nanjing University, Nanjing, China

Aug,1999 ~ Jul,2002 Ph.D.
Dept. of Computational Science, National University of Singapore, Singapore

Working experience

Jan,2004 ~ Sep,2007 PI, Associate professor, Assistant Director
ShangHai Center for Bioinfomation Technology

Oct,2007 ~ to Date Professor
Dept. of Bioinformatics, School of Life Science and Biotechnology, Tongji university

Major Grants Received

1. "TCM modernization" National Key Research Program (2017YFC1700205)
            Computational modeling and systematics analysis of TCM recipes
2. "Precision Medicine" National Key Research Program: (2017YFC0908400)
            Clinical Omics databank of China major diseases and rare diseases.
3. "Major projects of infectious disease": (2012ZX10005001, 2009ZX10004-601)
            Research Platform of TCM syndromes. (1 million RMB)
4. "973" National Key Basic Research Program of China: (2010CB833601)
            Bioinformatics Study of Antibody-Antigen molecular recognition.
5. "973" National Key Basic Research Program of China: (2004CB720103)
            Bioinformatics study of the structure-function relationship for antibody.
6. "863" National High-Tech Program: (2006AA02Z317)
            Bioinformatics Platform for Herbal Mechanistic Study.
7. National Natural Science Foundation of China: (31171272)
            Bioinformatics study on antigenic drift of HA protein for H3N2 influenza virus.

Representative Publications

[1] Zhou, C., Chen, Z., Zhang, L., Yan, D., Mao, T., Tang, K., . . . Cao, Z. (2019). SEPPA 3.0-enhanced spatial epitope prediction enabling glycoprotein antigens. Nucleic Acids Res, 47(W1), W388-W394.
[2] Qiu, T., Yang, Y., Qiu, J., Huang, Y., Xu, T., Xiao, H., . . . Cao, Z. (2018). CE-BLAST makes it possible to compute antigenic similarity for newly emerging pathogens. Nat Commun, 9(1), 1772.
[3] Sheng, Z., Sun, Y., Yin, Z., Tang, K., & Cao, Z. (2018). Advances in computational approaches in identifying synergistic drug combinations. Brief Bioinform, 19(6), 1172-1182.
[4] Sun, Y., Sheng, Z., Ma, C., Tang, K., Zhu, R., Wu, Z., . . . Cao, Z. (2015). Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. Nat Commun, 6, 8481.
[5] Qi, T., Qiu, T., Zhang, Q., Tang, K., Fan, Y., Qiu, J., . . . Cao, Z. (2014). SEPPA 2.0--more refined server to predict spatial epitope considering species of immune host and subcellular localization of protein antigen. Nucleic Acids Res, 42(Web Server issue), W59-63.
[6] Ye, H., Ye, L., Kang, H., Zhang, D., Tao, L., Tang, K., . . . Cao, Z. (2011). HIT: linking herbal active ingredients to targets. Nucleic Acids Res, 39(Database issue), D1055-1059.
[7] Sun, J., Wu, D., Xu, T., Wang, X., Xu, X., Tao, L., . . . Cao, Z. (2009). SEPPA: a computational server for spatial epitope prediction of protein antigens. Nucleic Acids Res, 37(Web Server issue), W612-616.
[8] Jia, J., Zhu, F., Ma, X., Cao, Z., Cao, Z. W., Li, Y., . . . Chen, Y. Z. (2009). Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov, 8(2), 111-128.
[9] Cao, Z. W., Xue, Y., Han, L. Y., Xie, B., Zhou, H., Zheng, C. J., . . . Chen, Y. Z. (2004). MoViES: molecular vibrations evaluation server for analysis of fluctuational dynamics of proteins and nucleic acids. Nucleic Acids Res, 32(Web Server issue), W679-685.